Last 12 months
Inside the activity.
2 purchase rows · 30 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 2 | 3 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 1 |
| Mar 2026 | 0 | 1 |
| Apr 2026 | 0 | 1 |
| May 2026 | 0 | 3 |
| Jun 2026 | 0 | 5 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 7 |
| Sep 2026 | 0 | 5 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 09, 2016 Filed Sep 14, 2016 00:30 UTC | OtherCommon Stock | 11,833 | $95.80 | $1,133,601.40 |
DisclosureSEC source: 0001093557-16-000691 · edgardoc.xml · nonDerivative · entry 5 VALDES JORGE A · CIK 0001343856 · CTO 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 13,383 F4 · shares: Shares were transferred from direct ownership to ownership under the Valdes-Lopez-Calleja Family Trust upon vesting of previously awarded restricted stock units. F5 · ownership.nature: Shares are held by the Valdes-Lopez-Calleja Family Trust U/A/D 05/18/2011, with respect to which the reporting person is a trustee. Read SEC document |
|
| September 09, 2016 Filed Sep 14, 2016 00:30 UTC | OtherCommon Stock | 7,500 | $95.80 | $718,500.00 |
DisclosureSEC source: 0001093557-16-000691 · edgardoc.xml · nonDerivative · entry 4 VALDES JORGE A · CIK 0001343856 · CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,334 F4 · shares: Shares were transferred from direct ownership to ownership under the Valdes-Lopez-Calleja Family Trust upon vesting of previously awarded restricted stock units. F3 · balance_after: Included in this number are 72,334 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest on March 8, 2019, 22,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 11,834 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
|
| September 09, 2016 Filed Sep 14, 2016 00:30 UTC | OtherCommon Stock | 11,833 | $95.80 | $1,133,601.40 |
DisclosureSEC source: 0001093557-16-000691 · edgardoc.xml · nonDerivative · entry 3 VALDES JORGE A · CIK 0001343856 · CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,834 F4 · shares: Shares were transferred from direct ownership to ownership under the Valdes-Lopez-Calleja Family Trust upon vesting of previously awarded restricted stock units. F3 · balance_after: Included in this number are 72,334 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest on March 8, 2019, 22,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 11,834 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
|
| September 09, 2016 Filed Sep 14, 2016 00:30 UTC | SaleCommon Stock | 12,000 | $93.66 | $1,123,909.20 |
DisclosureSEC source: 0001093557-16-000691 · edgardoc.xml · nonDerivative · entry 2 VALDES JORGE A · CIK 0001343856 · CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,667 F1 · shares: On March 7, 2016 Mr. Valdes adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Valdes. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $92.85 to $94.98. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F3 · balance_after: Included in this number are 72,334 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest on March 8, 2019, 22,500 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 11,834 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
|
| September 09, 2016 Filed Sep 14, 2016 00:30 UTC | Exercise / conversionCommon Stock | 12,000 | $7.63 | $91,560.00 |
DisclosureSEC source: 0001093557-16-000691 · edgardoc.xml · nonDerivative · entry 1 VALDES JORGE A · CIK 0001343856 · CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,667 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
|
| September 09, 2016 Filed Sep 14, 2016 00:29 UTC |
GREGG TERRANCE HDirector · Executive Chairman
|
Disposition to issuerCommon Stock | 2,203 | $93.72 | $206,470.89 |
DisclosureSEC source: 0001093557-16-000689 · edgardoc.xml · nonDerivative · entry 1 GREGG TERRANCE H · CIK 0001236388 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 449,283 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 64,469 unvested restricted stock units, 34,000 of which were granted on March 8, 2016 and will vest on March 8, 2017 and 30,469 unvested restricted stock units granted on March 8, 2014, 5,078 of which shall vest each month through March 8, 2017. Read SEC document |
| September 09, 2016 Filed Sep 14, 2016 00:30 UTC |
SAYER KEVIN RDirector · President & CEO
|
Disposition to issuerCommon Stock | 13,335 | $93.72 | $1,249,790.87 |
DisclosureSEC source: 0001093557-16-000690 · edgardoc.xml · nonDerivative · entry 2 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 313,891 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 160,000 unvested restricted stock units, 90,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 45,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 25,000 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 09, 2016 Filed Sep 14, 2016 00:30 UTC |
SAYER KEVIN RDirector · President & CEO
|
Disposition to issuerCommon Stock | 8,001 | $93.72 | $749,874.52 |
DisclosureSEC source: 0001093557-16-000690 · edgardoc.xml · nonDerivative · entry 1 SAYER KEVIN R · CIK 0001286858 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,226 F1 · shares: These shares were sold to cover the Company's tax withholding obligation that accrued in connection with the vesting of restricted stock units previously granted. F2 · balance_after: Included in this number are 160,000 unvested restricted stock units, 90,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 45,000 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 25,000 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 08, 2016 Filed Sep 10, 2016 00:48 UTC |
GREGG TERRANCE HDirector · Executive Chairman
|
SaleCommon Stock | 5,145 | $95.59 | $491,829.59 |
DisclosureSEC source: 0001093557-16-000676 · edgardoc.xml · nonDerivative · entry 2 GREGG TERRANCE H · CIK 0001236388 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 65,882 F3 · price: This transaction was executed in multiple trades at prices ranging from $95.46 to $95.77. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: Shares are held by the Gregg Family Trust U/A/D 12/23/1998, with respect to which the reporting person is a trustee. Read SEC document |
| September 07, 2016 Filed Sep 10, 2016 00:50 UTC |
FOLETTA MARK GDirector
|
SaleCommon Stock | 1,800 | $94.63 | $170,325.00 |
DisclosureSEC source: 0001093557-16-000678 · edgardoc.xml · nonDerivative · entry 1 FOLETTA MARK G · CIK 0001236389 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,643 F1 · price: This transaction was executed in multiple trades at prices ranging from $94.60 to $94.68. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · balance_after: Included in this number are 10,027 unvested restricted stock units, 5,450 of which were granted on May 25, 2016 and shall vest on May 25, 2017 and 4,577 of which were granted on November 17, 2014 and shall vest through November 17, 2017. Read SEC document |
| September 07, 2016 Filed Sep 10, 2016 00:49 UTC |
Balo Andrew KEVP, Clinical and Regulatory
|
Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 4,999 | $94.45 Strike: $3.19 | $472,155.55 |
DisclosureSEC source: 0001093557-16-000677 · edgardoc.xml · derivative · entry 3 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,999 shares Expires 2018-12-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2016 Filed Sep 10, 2016 00:49 UTC |
Balo Andrew KEVP, Clinical and Regulatory
|
SaleCommon Stock | 4,999 | $94.45 | $472,155.55 |
DisclosureSEC source: 0001093557-16-000677 · edgardoc.xml · nonDerivative · entry 2 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,010 F1 · shares: On December 11, 2015, Mr. Balo adopted a 10b5-1 Plan. This 10b5-1 Plan allows the orderly disposition of shares owned by Mr. Balo. The shares set forth above were sold pursuant to the 10b5-1 Plan. F2 · balance_after: Included in this number are 70,084 unvested restricted stock units, 38,000 of which were granted on March 8, 2016 and shall vest through March 8, 2019, 23,750 of which were granted on March 8, 2015 and shall vest through March 8, 2018 and 8,334 of which were granted on March 8, 2014 and shall vest through March 8, 2017. Read SEC document |
| September 07, 2016 Filed Sep 10, 2016 00:49 UTC |
Balo Andrew KEVP, Clinical and Regulatory
|
Exercise / conversionCommon Stock | 4,999 | $3.19 | $15,946.81 |
DisclosureSEC source: 0001093557-16-000677 · edgardoc.xml · nonDerivative · entry 1 Balo Andrew K · CIK 0001323190 · EVP, Clinical and Regulatory 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,009 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 07, 2016 Filed Sep 10, 2016 00:48 UTC |
GREGG TERRANCE HDirector · Executive Chairman
|
SaleCommon Stock | 5,595 | $95.01 | $531,570.88 |
DisclosureSEC source: 0001093557-16-000676 · edgardoc.xml · nonDerivative · entry 1 GREGG TERRANCE H · CIK 0001236388 · Director · Executive Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · by Trust Disclosed balance after: 71,027 F1 · price: This transaction was executed in multiple trades at prices ranging from $95.00 and $95.04. The price above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected. F2 · ownership.nature: Shares are held by the Gregg Family Trust U/A/D 12/23/1998, with respect to which the reporting person is a trustee. Read SEC document |
| September 01, 2016 Filed Sep 6, 2016 19:34 UTC |
LORD JONATHAN T MDDirector
|
SaleCommon Stock | 10,000 | $91.50 | $915,000.00 |
DisclosureSEC source: 0001093557-16-000672 · edgardoc.xml · nonDerivative · entry 1 LORD JONATHAN T MD · CIK 0001112980 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,820 F1 · balance_after: Since the date of the reporting person's last Form 4, 63,553 shares of Dexcom Inc. Common stock were transferred to his former spouse pursuant to a domestic relations order. Included in this number are 4,791 unvested restricted stock units which were granted on May 25, 2016 and shall vest on May 25, 2017. Read SEC document |
| May 08, 2014 Filed Sep 15, 2016 00:44 UTC |
KAHN BARBARADirector
|
SaleCommon Stock | 7,500 | $30.11 | $225,854.25 |
DisclosureSEC source: 0001093557-16-000702 · edgardoc.xml · nonDerivative · entry 1 KAHN BARBARA · CIK 0001520391 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,791 F1 · shares: Inadvertently filed late due to an administrative error. F2 · balance_after: Included in this number are 4,791 unvested restricted stock units which were granted on May 25, 2016 and shall vest on May 25, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.